Histone deacetylase inhibitors (HDACis) are a promising class of anticancer epigenetic drugs, however, molecular factors influencing the responses of individual tumors to HDACi therapies remain obscure. Here, we sought to identify genes associated with HDACi resistance in gastric cancer. Treating a panel of 17 gastric cancer cell lines with multiple HDACi compounds (trichostatin A, SAHA and MS275), we identified two distinct classes of lines exhibiting either HDACi sensitivity or resistance. Genomic comparisons between the sensitive and resistant classes using two independent microarray platforms identified RNH1, encoding a ribonuclease inhibitor, as a gene highly expressed in HDACi-resistant lines. Using genetic knockdown and overexpression assays, we show that RNH1 is both necessary and sufficient to induce HDACi resistance, and that RNH1 is likely to mediate this resistance through the dampening of HDACi-induced reactive oxygen species (ROS) in cancer cells. The discovery of RNH1 as a regulator of HDACi resistance in gastric cancer highlights a functional role for ROS induction in the cellular effects of this important drug class.
INTRODUCTION
Epigenetic alterations, such as changes in DNA methylation and histone acetylation/methylation, 1,2 are widely observed in many cancers. 3 Epigenetic alterations are believed to induce changes in chromatin structure, with subsequent effects on gene expression. 4, 5 In tumors, epigenetic alterations can cause the transcriptional silencing of tumor-suppressor genes, 3 contributing to carcinogenesis and malignant progression. In the cancer therapeutics field, intense activity has been directed toward developing inhibitors of enzymes involved in establishing and maintaining cancer-associated epigenetic states. 6 One important class of these 'epigenetic drugs' are histone deacetylase inhibitors (HDACis). Several types of HDACis exist, and may exert either panor specific/selective effects on distinct cellular HDACs. For example, vorinostat and trichostatin A (TSA) inhibit class I and II HDACs, whereas entinostat (MS 275) specifically inhibits HDAC1, 2 and 3. 4, 7 At least 16 HDACis are currently being tested in phase I and II clinical trials in a variety of tumor types, 4, [8] [9] [10] and vorinostat has been clinically approved for the treatment of advanced and refractory primary cutaneous T-cell lymphoma. 11 Notably, these clinical studies have now clearly demonstrated that HDACis are typically associated with variable efficacy and specificity in different patients, with average response rates ranging from 10 to 58%. 4 Identifying genes regulating HDACi sensitivity in different tumor types might provide insights into the mechanisms of action of these drugs, and strategies for targeting these compounds to those patients most likely to respond. Some previous examples of genes regulating HDAC inhibitor sensitivity include STAT1 in colon cancer cells and HR23B in cutaneous T-cell lymphoma. 12 Gastric cancer is the second leading cause of cancer-related death worldwide. 13, 14 Most patients are diagnosed at advanced disease stages when currently used chemotherapy and radiotherapy regimens typically have poor efficacy. 15 New molecularly targeted therapeutic approaches for gastric cancer are thus urgently needed. Previous studies have highlighted a significant role for histone deacetylation in gastric carcinogenesis. 16, 17 Aberrant activation of HDACs in gastric cancer cells have been shown to repress the expression of genes regulating proliferation, migration, angiogenesis, invasion and metastasis. 18, 19 Global gene expression studies have also suggested that HDACis (for example, vorinostat and TSA) may prove particularly efficacious in gastric cancer. 20 In clinical studies, HDAC1, HDAC2 and HDAC3 have been reported to be highly expressed in gastric tumors, with the high expression of all three HDACs being significantly associated with nodal tumor spread and decreased overall patient survival. 21 HDAC1 expression has been proposed as a risk stratification biomarker for gastric cancer patients receiving chemotherapy, 22 and clinical trials investigating the efficacy of HDACis (vorinostat) with radiotherapy in gastric cancer have been initiated. 23 To date, however, there have been no reports identifying genes regulating HDACi resistance in gastric cancer.
In this study, we conducted HDACi drug response assays and integrated genomic analysis across a panel of gastric cancer cell lines. We found that gastric cancer cell lines display a wide variety of responses to HDACi treatment, and identified ribonuclease inhibitor (RNH1) as a modulator of HDACi resistance in gastric cancer cells. We provide evidence that the ability of RNH1 to modulate HDACi resistance lies in its ability to regulate levels of reactive oxygen species (ROS) in cells induced by HDACi treatment. These results suggest that the redox status of a cancer cell, both baseline and after drug treatment, may have an important role in determining sensitivity or resistance to HDACi therapy.
RESULTS
Gastric cancer cell lines exhibit differential sensitivity to HDAC inhibitors Previous studies have suggested that individual gastric cancers can display differing responses to HDACi treatment. 9 To identify gastric cancer cell lines exhibiting differential sensitivities to HDACi compounds, we treated 17 gastric lines with increasing doses of TSA, a pan-HDACi, to determine GI50 values (referring to the drug concentration required to cause 50% cell growth inhibition relative to untreated controls; Figure 1a ). In parallel, we also determined LC20 values (referring to the drug concentration required to cause 20% cell reduction relative to untreated controls; Figure 1b) . Five cell lines with the highest GI50 values (YCC3, YCC7, YCC10, MKN1 and MKN7) were designated as potential TSA-resistant gastric cancer cell lines, and five cell lines (YCC11, AGS, IST1, SCH and AZ521) with lower GI50 values (o200 nM) and lowest LC20 values (o200 nM) relative to other lines (both GI50 and LC20 values 4400 nM, most LC20s 4800 nM) were designated as TSA-sensitive lines. There was a 410 Â difference in the GI50 values between the sensitive and resistant groups. This result shows that different gastric lines can indeed demonstrate differential sensitivities to HDAC inhibitor treatment.
Inhibition of cell proliferation by TSA could be due to several different mechanisms, including induction of apoptosis, cell growth arrest and senescence. To clarify which of these mechanisms might explain the effects of TSA, we tested the TSA-treated cells for the presence of cleaved poly (ADP-ribose) polymerase (PARP), a well-established apoptosis marker. In HDACi-sensitive lines, we observed robust induction of cleaved PARP following TSA treatment. In contrast, cleaved PARP was not observed in most of the HDACi-resistant lines, with the exception of MKN1 and YCC10 (Figure 1c) . Subsequent experiments analyzing TSA at longer treatment durations (48 h) revealed that MKN1 and YCC10 cells were modestly sensitive to TSA compared with other resistant lines (YCC3) (Supplementary Figure 1A) . We thus elected to exclude these two lines (MKN1 and YCC10) from the HDACi-resistant group in subsequent analysis. Similar results were also obtained using cleaved caspase 3, another marker of apoptosis (Supplementary Figure 1C) . These results suggest that the cell proliferation inhibition of HDACis is likely to involve the induction of apoptosis. As a third measure to verify the differential sensitivities of the sensitive and resistant lines to HDACi treatment, we conducted soft-agar colony formation assays. As shown in Figures 1d and e, after 3 weeks of TSA treatment, sensitive lines showed significantly decreased colony formation rates compared with untreated controls, whereas colony formation inhibition could not be observed in resistant lines (YCC3 and YCC7).
To determine if the cell line sensitivity profiles might be specific to TSA or also extendable to other HDACi compounds, we treated the gastric lines with two other HDACis (SAHA and MS275). Like TSA, SAHA is a pan-HDACi of the hydroxamate class, whereas MS275 is a benzamide class I specific HDACi. Similar drug sensitivity differences were observed with both SAHA and MS275 to the original TSA results (Supplementary Figure 2) . These results indicate that the TSA-sensitive lines are likely to exhibit broad-spectrum sensitivity to multiple HDACi compounds.
HDACis are believed to act by inhibiting histone deactylase activity, resulting in enhancements of histone acetylation levels and increased gene expression. 24 To assess if the TSA-sensitive and -resistant lines might be associated with differences in their baseline or treatment-induced histone acetylation profiles, we determined histone 3 (lysine 9) and histone 4 acetylation (lysine 12) levels in three sensitive and three resistant lines before and after HDACi treatment. These experiments were performed at TSA concentrations sufficient to trigger a robust apoptotic response in sensitive lines. H3 and H4 acetylation levels were observed to be similarly increased in both sensitive and resistant cell line groups after TSA treatment. In addition, p21 upregulation by HDAC inhibitor treatment has been widely observed in cancer cells. 25, 26 Interestingly, we found that TSA treatment also induced p21 upregulation in both sensitive and resistant GC cells (Supplementary Figure 2) . These results suggest that both histone acetylation enhancement and p21 induction are likely not sufficient to trigger growth arrest and apoptosis in gastric cancer cells. Additional factors may thus contribute to the cellular sensitivity of gastric cancer cells to HDACis.
RNH1 is highly expressed in HDAC inhibitor-resistant gastric cancer cells To identify factors regulating the cellular sensitivity of gastric cancer cells to HDACis, we examined genes differentially expressed between the sensitive and resistant lines. To reduce the possibility of false-positive results, we adopted an integrated genomic strategy where we combined gene expression profiles of the cell lines from two different commercially available microarray platforms (Affymetrix and Illumina), focusing on genes commonly identified by both platforms. On the Affymetrix platform, we identified 1231 genes differentially regulated between HDACisensitive and -resistant lines (Po0.05; fold change 41.5) and 1165 genes on the Illumina platform at the same significance threshold, representing 514 genes commonly identified by both platforms. Among these genes, we then imposed a q-value (false discovery rate) filter of o0.3 to select the top seven candidates. These included RNH1, STAT1, ELF, CXCL5, RAB40B, BLCAP and SGPP2 (Figure 2a ), which were all highly expressed in the resistant lines. Notably, among these seven genes we identified STAT1, a gene previously associated with HDACi resistance in colon cancer 27 this re-discovery provides confidence in the robustness of our results. We then extended our results from gene expression to the protein level, because of the possibility of an imperfect correlation between gene and protein expression. 28, 29 Western blotting assays using antibodies directed to these candidate genes revealed that two genes, STAT1 and RNH1 (highlighted in bold in Figure 2b ), exhibited higher protein levels in HDACi-resistant lines compared with sensitive lines. In contrast, similar protein expression trends were not observed for the other four candidates (high-quality antibodies were not available for BLCAP). We thus elected to focus on RNH1 for further characterization.
To examine patterns of RNH1 expression in gastric cell lines beyond the original eight lines used in the microarray analysis, we performed RNH1 western blotting on an additional six gastric lines identified in Figure 1 as being sensitive to HDACis. With the exception of NUGC3 cells, the other five lines exhibited lower levels of RNH1 protein expression compared with HDACis-resistant YCC3 cells (Supplementary Figure 3D) . These results thus suggest that levels of RNH1 protein expression are negatively correlated to HDACi sensitivity in gastric cancer.
RNH1 silencing and overexpression causes HDAC inhibitor sensitivity and resistance, respectively To investigate the functional role of RNH1 on gastric cancer HDACi sensitivity, we conducted genetic knockdown and overexpression experiments. Stable knock-down of RNH1 was confirmed by quantitative PCR and western blotting analysis, using two distinct and non-overlapping RNH1 short hairpin RNAs (shRNAs) in two HDACi-resistant cell lines, YCC3 and YCC7 ( To confirm these findings by other cellular indices, we then conducted cell death and colony formation assays. As shown in Figure 3b , RNH1-silenced YCC3 and YCC7 cells exhibited increased PARP cleavage on TSA treatment. Moreover, RNH1-silenced cells also exhibited decreased colony formation capacities after TSA treatment, by about 2-to 4-fold (Figures 3c and d, Supplementary Figure 6A ). Similar results were observed when TSA was replaced by SAHA or MS275, two other HDACi compounds ( Figure 3 and Supplementary Figure 6A ). Taken collectively, these results observed in two independent HDACi-resistant gastric lines suggests that inhibiting RNH1 can sensitize gastric cancer cells to HDACi treatment. We then performed the reciprocal experiment by overexpressing wild-type RNH1 in the HDACi-sensitive lines AZ521 and YCC11. Ectopic overexpression of RNH1 in these cell lines was confirmed to be within physiological parameters (Supplementary Figure 4) , and associated with decreased growth (Supplementary Figure 5) . As shown in Figure 4 and Supplementary Figure 6 , overexpression of wild-type RNH1 in these lines significantly increased their TSA GI50 values, attenuated production of cleaved PARP and decreased the effects on colony formation inhibition by TSA. Similar results were observed when TSA was replaced by SAHA or MS275, two other HDACi compounds (Figure 4,  Supplementary Figure 6 ). These results provide further evidence that high levels of RNH1 are sufficient to render gastric cancer cells resistant to HDACi therapy.
Gastric cancer HDAC inhibitor sensitivity requires inhibitorinduced ROS production modulated by RNH1 RNH1 encodes a ribonuclease inhibitor protein, which is mainly distributed in the cytoplasm. 30, 31 Proposed biological roles of RNH1 include modulating the biological activities of cellular ribonucleases and as an oxidative sensor to monitor the redox status of a cell. [32] [33] [34] As ROS production has been proposed to have an important role in HDACi-induced cancer cell death, 35 we hypothesized that RNH1 might contribute to HDACi resistance by suppressing drug-induced ROS production in gastric cancer cells. To investigate this possibility, we first measured levels of druginduced ROS in both the sensitive and resistant gastric cell lines, at early treatment time points. As shown in Figure 5a , TSA induced higher ROS levels in HDACi-sensitive lines, compared with resistant lines (Po0.01). The average level of ROS production in the sensitive group was about fivefold higher than the resistant RNH1 regulation of HDAC inhibitor sensitivity Y Zhu et al group, with the exception of SCH cells, which exhibited a relatively low level of ROS production. This result suggests that gastric cancer sensitivity to HDAC inhibitor treatment is associated with their ability of cells to produce ROS on drug exposure. To ask if drug-induced ROS might be necessary for HDACiinduced cancer cell death, we then exposed gastric cancer cells to two compounds known to alter cellular ROS levels-phenethyl isothiocyanate (PEITC), which is known to increase ROS levels, 36 and L-glutathione (GSH), which is known to scavenge and reduce ROS. 37 Interestingly, PEITC has been previously reported to enhance the cytotoxicity of HDAC inhibitors in leukemia. 38 As shown in Figure 5c , PEITC co-treatment (5 mM) enhanced the ability of TSA to inhibit proliferation in both YCC3 cells and in RNH1-overexpressing AZ521 cells, at TSA concentrations that would not normally affect cellular proliferation in these cells (200 nM TSA).The PEITC-TSA combination also effectively induced much higher ROS production compared with the monotherapy-treated lines. Similar effects of the PEITC-TSA combination were also observed in YCC7 cells or in RNH1-overexpressing YCC11 cells (Supplementary Figure 7B) .
Conversely, we found that pre-incubating cells with GSH rendered them resistant to HDAC inhibitor-induced cell death. Specifically, GSH pre-treatment rescued AZ521 cells and RNH1-silenced YCC3 cells from TSA-induced growth inhibition, at TSA concentrations normally sufficient to induce robust cell death in the parental cells (200 nM for AZ521 and 400 nM for YCC3 with RNH1-silencing). This resistance caused by GSH pre-treatment was also associated with a parallel decrease in HDACi-induced ROS production (Figure 5d ). Similar results were also observed in both YCC11 cells or RNH1-silenced YCC7 cells (Supplementary Figure 7C) . These results suggest that induction of ROS by HDACis is necessary for the induction of proliferation inhibition and cell death in gastric cancer cells.
To explore the role of RNH1 in ROS production induced by HDACi treatment, we then compared drug-induced ROS levels between RNH1-silenced YCC3 cells and wild-type YCC3 cells, and RNH1 overexpressing AZ521 cells to parental AZ521 cells. RNH1-silenced YCC3 cells produced significantly higher levels of ROS on HDACi treatment, by about 10-to 17-fold (Po0.001) compared with control cells (Figure 5b) . Conversely, RNH1-overexpressing AZ521 cells exhibited significantly decreased drug-induced ROS production compared with parental cells (Po0.01; B2-fold) (Figure 5b) . Similar results were observed in both RNH1-silenced YCC7 cells (ROS levels increased B2-fold) and also in RNH1-overexpressing YCC11 cells (ROS levels decreased B5-fold) (Supplementary Figure 7A) . These results indicate that the levels of cellular RNH1 likely represent an important determinant in the ability of gastric cancer cells to produce ROS in response to HDACi therapy. RNH1 expression levels are correlated to HDAC inhibitor response in normal gastric epithelial cells One appealing characteristic of HDACis is that non-cancerous cells typically exhibit high in vitro tolerance to these drugs. 39 We thus explored if RNH1 expression levels might be associated with HDACi resistance in normal gastric epithelial cells, and also cancer cells of non-gastric origin. We exposed two normal gastric epithelial lines (HFE145 and GES1) to increasing concentrations of TSA. Both cell lines exhibited GI50 values above 800 nM, an even greater level of resistance than YCC3 or YCC7 cells ( Figure 6 ). Importantly, both normal gastric lines expressed high RNH1 levels, similar to YCC3 cells (Figure 6a ). This observation is consistent with the hypothesis of RNH1 contributing to HDACi resistance in normal gastric cells.
DISCUSSION
HDACis have aroused tremendous interest as a potential anticancer therapy, particularly due to their ability to selectively induce apoptosis in cancer cells while sparing non-malignant tissues. 40 In this study, we sought to identify potential genes regulating HDACi sensitivity in gastric cancer, motivated by recent reports of their potency in this tumor type. 20, 21 Using both twodimensional (growth inhibition, apoptosis) and three-dimensional (colony formation) assays, we found that different gastric cancer cell lines displayed significantly different sensitivities to HDACis, up to 410-fold in some cases (GI50 of the most sensitive line, YCC11-32.6 nM, GI50 of the most resistant line MKN7-4800 nM). The differences in sensitivity were common to different HDACis (TSA, SAHA and MS275), suggesting that these responses are generalizable to this drug class. Our in vitro findings render it plausible that primary gastric cancers may also exhibit similarly heterogeneous responses to HDACis in vivo like cutaneous T-cell lymphoma patients. 41, 42 HDACis have been proposed to inhibit cellular proliferation and mediate cell death through several pathways. For instance, HDACis have been shown to induce G1 cell cycle arrest through induction of the cyclin-dependent kinase inhibitor p21 WAF/CIP1 ; 43 and altered chromatin structures caused by HDAC hyperacetylation can elicit a DNA damage response. 44 HDACis can also inhibit the spindle assembly checkpoint through disruption of spindle checkpoint proteins BubRi, hBub1, Mad2, CENP-F and CENP-E. 45 In addition, HDACi compounds have been shown to induce apoptosis through both the extrinsic (death receptor) and the intrinsic (mitochondrial) pathways. 46 In the extrinsic pathway, HDACis can selectively upregulate death receptors and ligands in tumor cells, 47, 48 whereas in the intrinsic pathway, HDACis can downregulate pro-survival proteins (for example, Bcl-2 and Bcl-I L ), and upregulate pro-apoptotic proteins (Bim, Bak and Bax). 49 Most relevant to this study, it has also been shown that HDACis can stimulate ROS generation, and that treating cells with antioxidants can reduce HDACi anticancer activity. 35, 39, 50, 51 These latter studies suggest that oxidative stress may have an important role in tumor cell death induced by HDACis, as oxidative stress can promote apoptosis through intrinsic pathway activation. 52 Consistent with this idea, we also found that ROS generation by HDACis was much higher in sensitive gastric cancer cells than resistant cells.
Previous studies have identified a handful of genes associated with HDAC inhibitor sensitivity. In colon cancer, inducible expression of mutant Ras-sensitized cells to HDACi-induced apoptosis and this was shown to occur through the downregulation of STAT1.
27 HR23B was identified as a gene whose lossof-function imparted sensitivity to HDAC inhibitors in cutaneous T-cell lymphoma cells. 12 Interestingly, in our own analysis, STAT1 was also identified as one of the top candidate genes highly expressed in resistant cell groups, which is consistent with the colon cancer study. The re-identification of STAT1 as a gene associated with HDACi resistance provides confidence in the robustness of our results.
Our major discovery in this project was the discovery of RNH1 as a gene associated with HDAC inhibitor sensitivity in gastric cancer. A cytosolic protein, RNH1 was initially identified as an inhibitor of secretory and intracellular ribonucleases. 53, 54 In the context of cancer, conflicting data exists regarding whether RNH1 is pro or anti-oncogenic. For example, in some studies RNH1 expression has been reported to correlate positively with cell proliferation and tumorigenesis. 55, 56 However, others have found that high RNH1 expression could decrease angiogenesis and tumor formation in mouse xenografts, and in bladder cancer RNH1 knock-down promoted growth and metastasis. 57, 58 In the noncancer literature, several recent studies have suggested an important role for RNH1 in protecting cells against oxidative damage. Specifically, RNH1 overexpression in rat glial cells conferred protection against hydrogen peroxide-induced stress, and RNH1 injections into mice also conferred protection from oxidation-induced liver injuries by carbon tetrachloride exposure. 59 RNH1 has also been found to contribute to intracellular redox homeostasis in a variety of malignant and non-malignant cell types. 34 Previous publications focusing on the relationship between ROS and HDACi sensitivity have focused on the role of thioredoxin and its inhibitor, thioredoxin-binding protein 2, in regulating ROS 39, 51 In this study, our data, supported by both genetic knockdown and overexpression experiments, suggests that high RNH1 levels may also cause resistance to HDACi through the suppression of HDACi-induced ROS. Supporting this finding, we found that the potency of HDACis could be enhanced by co-administration with the ROS inducer PEITC, and that conversely HDACi potency could be decreased by pre-treatment with the ROS scavenging compound GSH. Interestingly, genetic knockdown or overexpression of RNH1 did not seem to influence the sensitivity of gastric cancer cells to other drugs such as fluorouracil and cisplatin (Supplementary Figure 8) , although these drugs are also known to induce ROS production in cancer cells. 60, 61 This result suggests that ROS production has a more important role in HDACis-induced gastric cancer cell death compared with other cytotoxic drugs.
In conclusion, we have identified RNH1 as a contributor to HDACi resistance in gastric cancer cells through genomic analysis. We propose that RNH1 mediates this effect through its ability to regulate HDACi-induced ROS levels. It should be noted that currently our results regarding RNH1 are primarily based on in vitro data. An important area for future research will be to investigate if RNH1 levels in primary tumor samples are also correlated with clinical responses to HDACi treatment. Such an analysis would require access to gene expression profiles or tissue samples obtained from patients undergoing HDAC therapy, and for which treatment responses are known. Finally, it is possible that targeting RNH1, or enhancing HDACi-induced ROS generation, may represent a promising approach to overcome HDACi resistance in the clinical setting.
MATERIALS AND METHODS

Cell lines and drug treatments
Cell lines AGS N87, and Hs746T were purchased from the American Type Culture Collection (Manassas, VA, USA). AZ521, Ist1, TMK1, MKN1, MKN7, MKN28 and IM95 cells were obtained from the Japan Health Science Research Resource Bank (Tokyo, Japan). SCH cells were provided by Yoshiaki Ito (Cancer Science Institute of Singapore, Singapore). YCC cells (YCC3, YCC6, YCC7, YCC11 and YCC16) were a gift from Sun-Young Rha (Yonsei Cancer Center, South Korea). AGS, IST1, AZ521, SCH, MKN7 and GES1 (normal gastric epithelial) cells were maintained in RPMI 1640 medium (Sigma, St Louis, MO, USA) with 10% fetal bovine serum (Gemini Bio-Products, West Sacremento, CA, USA). YCC cells were maintained in minimum essential medium with 10% fetal bovine serum. IM95, HS746T, HFE145, HepG2 and HCT116 cells were maintained in Dulbecco's modified Eagle's medium with 10% fetal bovine serum. All lines were grown in an incubator at 37 1 with 5% CO 2 . HDAC inhibitors TSA (from Sigma), vorinostat (SAHA) and MS275 (Enzo Life Sciences, Exeter, UK) were utilized as experimental drugs. Cells were treated using drug concentrations previously established in the literature, specifically 50-800 nM TSA, 62 0.625-10 mm SAHA, 63 3.125-50 mM MS275 64 or dimethylsulphoxide only (control) for 24, 48 and/or 72 h. For molecular assays, cells were treated with 400 nM TSA or 5 mM SAHA or 30 mM MS275 unless otherwise specified.
Cell proliferation assay (MTS assay)
Cell proliferation assays were performed using a CellTiter96 Aqueous Nonradioactive Cell Proliferation Assay kit (Promega, Madison, WI, USA) following the manufacturer's instructions. Briefly, cells were seeded into 96-well plates at an initial density of 3000-5000 cells per well. A volume of 20 ml of MTS solution was added to each well and incubated for 4 h at 37 1C. After 30 min at room temperature, the plates were measured using a PerkinElmer plate reader (Wellesley, MA, USA). Assays were performed in triplicate, and the results were averaged over three independent experiments.
Colony formation assays
Base layers of 0.6% Gum Agar in 1 Â RPMI1640 or minimum essential medium and 10% fetal bovine serum were poured into six-well plates and allowed to harden at 4 1C. A total of 50 000 cells per well were seeded on top of the solidified base layer in complete media plus agar mixture at 37 1C. Plates were incubated at 37 1C in for 3-4 weeks, during which plates were fed drop-wise with complete media. After 3-4 weeks, plates were photographed using the Kodak GL 200 System (EpiWhite Illumination, Rochester, NY, USA). Assays were performed in triplicate, and the results were averaged over three independent experiments.
Western blotting
Cells were harvested in lysis buffer (10 mM Tris.Cl pH 7.5, 150 mM NaCl, 1% Triton X-114) for 1 h at 4 1C, and centrifuged at 800 g. Supernatants were incubated at 30 1C for 5-10 min and further centrifuged at room temperature, 300 g. Western blotting was performed on polyvinylidene were treated with TSA, the ROS scavenger GSH, or pre-treatment by GSH for 2 h followed by TSA. GSH/TSA-treated cells were observed to show resistance to TSAinduced proliferation inhibition, which is also associated with decreased ROS induction. *Po0.05 between control and TSA-treated cells. Differential gene expression analysis GC cell lines were profiled using Affymetrix Human Genome U133 plus GeneChips (HGU133 Plus 2.0; Affymetrix, Santa Clara, CA, USA) and Illumina Human-6 v2 Expression BeadChips (Illumina, San Diego, CA, USA). Gene expression profiles (both Affymetrix and Illumina arrays) were imported into Partek Genomics Suite 6.3 (Partek Inc., St Louis, MO, USA) using default Partek normalization parameters. Probe-level data were pre-processed, including background correction, normalization and summarization, using robust multi-array average analysis adjusted for probe sequence and GC content (GC-robust multi-array average). These values were then log 2 transformed. Background-adjusted, normalized values were then averaged to generate a single value under each gene ID. Differential expression analysis was performed using one-way analysis of variance between the HDAC inhibitor sensitive and resistant groups, using a filter of Po0.05. False discovery rates were calculated using the 'q-value' application in Partek software, and the standard was set as o0. 
Statistical analysis
Experiments were assessed by Student's unpaired t-test. P-values o0.05 were considered statistically significant.
